Table 2 |
||||
|
Frequency of microvascular and macrovascular complications by treatment |
||||
| Complication |
Metformin (/100 pt) |
Combination (/100 pt) |
Improvement |
|
|
|
||||
| Absolute |
Relative (%) |
|||
|
|
||||
| Nephropathy |
||||
| Microalbuminuria |
21.1 |
18.1 |
3.0 |
14.2 |
| Gross proteinuria |
18.8 |
13.4 |
5.4 |
28.7 |
| End stage renal disease |
5.9 |
4.4 |
1.5 |
25.4 |
| Retinopathy |
||||
| Background retinopathy |
30.7 |
23.7 |
7.0 |
22.7 |
| Macular edema: |
||||
| Detected |
25.4 |
20.6 |
4.7 |
18.7 |
| Photocoagulated |
24.3 |
19.9 |
4.5 |
18.4 |
| Proliferative retinopathy: |
||||
| detected |
12.3 |
7.9 |
4.5 |
36.3 |
| photocoagulated |
12.1 |
7.7 |
4.4 |
36.3 |
| Blindness |
9.4 |
8.0 |
1.4 |
14.9 |
| Neuropathy |
||||
| Foot ulcer |
21.1 |
16.3 |
4.8 |
22.7 |
| Neuropathy |
12.7 |
9.6 |
3.2 |
24.8 |
| 1st Lower-extremity amputation |
9.0 |
7.5 |
1.5 |
16.5 |
| 2nd Lower-extremity amputation |
5.1 |
4.3 |
0.7 |
14.6 |
| Macrovascular Disease |
||||
| Myocardial infarction |
15.0 |
14.6 |
0.4 |
2.4 |
| Stroke |
13.7 |
13.4 |
0.3 |
1.9 |
|
|
||||
|
Ward et al. Cost Effectiveness and Resource Allocation 2004 2:2 doi:10.1186/1478-7547-2-2 |
||||
